BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29358992)

  • 1. The role of pH in symptomatic relief and effective treatment of gastroesophageal reflux disease.
    Gąsiorowska A
    Prz Gastroenterol; 2017; 12(4):244-249. PubMed ID: 29358992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors in the management of gastroesophageal reflux disease.
    Hrelja N; Zerem E
    Med Arh; 2011; 65(1):52-5. PubMed ID: 21534455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of gastroesophageal reflux disease.
    Pettit M
    Pharm World Sci; 2005 Dec; 27(6):432-5. PubMed ID: 16341949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?
    Tack J; Fass R
    Aliment Pharmacol Ther; 2004 Feb; 19 Suppl 1():28-34. PubMed ID: 14725576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
    Azzam RS
    Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: current practice and future perspectives in the management of gastro-oesophageal reflux disease.
    Lambert R
    Aliment Pharmacol Ther; 1997 Aug; 11(4):651-62. PubMed ID: 9305472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Guidelines for the treatment of gastroesophageal reflux disease].
    Lee JH; Cho YK; Jeon SW; Kim JH; Kim NY; Lee JS; Bak YT;
    Korean J Gastroenterol; 2011 Feb; 57(2):57-66. PubMed ID: 21350318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms.
    Tougas G; Armstrong D
    Can J Gastroenterol; 1997 Sep; 11 Suppl B():51B-54B. PubMed ID: 9347179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
    Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
    J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Importance of pH control in the management of GERD.
    Hunt RH
    Arch Intern Med; 1999 Apr; 159(7):649-57. PubMed ID: 10218743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prokinetic approach to treatment of gastroesophageal reflux disease.
    Achem SR; Robinson M
    Dig Dis; 1998; 16(1):38-46. PubMed ID: 9549035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcomes of patients with symptomatic gastroesophageal reflux disease treated with vonoprazan.
    Shinozaki S; Osawa H; Kobayashi Y; Sakamoto H; Hayashi Y; Miura Y; Kawarai Lefor A; Yamamoto H
    Scand J Gastroenterol; 2018 Aug; 53(8):897-904. PubMed ID: 30056768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: gastric pH -- the most relevant predictor of benefit in reflux disease?
    Armstrong D
    Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 5():19-26; discussion 38-9. PubMed ID: 15456460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastroesophageal reflux disease: exaggerations, evidence and clinical practice.
    Ferreira CT; Carvalho Ed; Sdepanian VL; Morais MB; Vieira MC; Silva LR
    J Pediatr (Rio J); 2014; 90(2):105-18. PubMed ID: 24184302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Control of intragastric pH and its relationship to gastroesophageal reflux disease outcomes.
    Katz PO; Johnson DA
    J Clin Gastroenterol; 2011 Oct; 45(9):748-54. PubMed ID: 21694609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.